Nuveen Asset Management, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.8 - $7.25 $169,819 - $256,497	-35,379 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $1,526 - $2,398	334 Added 0.95%	35,379 $826,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $73,955 - $105,739	-20,774 Reduced 37.22%	35,045 $818,000
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $72,861 - $538,794	18,925 Added 51.3%	55,819 $1.3 Million
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $416,756 - $903,015	26,031 Added 239.63%	36,894 $1.06 Million
Q1 2020 May 14, 2020	BUY	$14.53 - $30.69 $157,839 - $333,385	10,863 New	10,863 $233,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.